Home / Intelligence / Webinars / What’s Keeping Payers Up at Night?
Available On Demand
The U.S. market access landscape is becoming increasingly competitive and complex. It is now more important than ever for drug manufacturers to keep abreast of what payers are thinking to maximize the likelihood of receiving favorable reimbursement outcomes.
Through in-depth and ongoing conversations with Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs), Trinity’s Value, Access and Pricing experts uncover what payers believe to be the most critical factors shaping pricing and market access decision-making for manufacturers over the next 6-24 months.
Key Topics
- The impact of biosimilar entry on the pricing and access landscape
- The different avenues of reimbursement for high-cost therapies
- Social determinants of health (SDOH) and the impact on payers
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More